Leerink Swann maintains an 'Outperform' on Corcept Therapeutics (CORT); Korlym Approved. Launch To Start On May 1
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $120.75 +1.45%
Rating Summary:
8 Buy, 8 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
8 Buy, 8 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Leerink Swann maintains an 'Outperform' on Corcept Therapeutics (NASDAQ: CORT) price target of $5.00.
Leerink analyst says, "CORT announced on Friday, 2/17, the approval of Korlym for the treatment of Cushing's syndrome. CORT hosted a conference call this morning to discuss the approval and the commercialization plans for Korlym...CORT expects to price the drug comparable to other orphan drugs and to announce the price near the time of the 5/1 launch. In addition, while the most frequent dose in the trial was 1200mg/day, the average dose has not been disclosed. Hence the average annual cost of therapy remains an open question. We currently estimate the annual cost of therapy will be $175k/yr."
For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.
Shares of Corcept Therapeutics closed at $3.03 yesterday.
Leerink analyst says, "CORT announced on Friday, 2/17, the approval of Korlym for the treatment of Cushing's syndrome. CORT hosted a conference call this morning to discuss the approval and the commercialization plans for Korlym...CORT expects to price the drug comparable to other orphan drugs and to announce the price near the time of the 5/1 launch. In addition, while the most frequent dose in the trial was 1200mg/day, the average dose has not been disclosed. Hence the average annual cost of therapy remains an open question. We currently estimate the annual cost of therapy will be $175k/yr."
For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.
Shares of Corcept Therapeutics closed at $3.03 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truist Securities Assumes Corcept Therapeutics (CORT) at Buy
- Hims and Hers (HIMS) PT Lowered to $35 at Barclays
- Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
